Inovio Pharmaceuticals Inc (INO) Receives Consensus Rating of “Hold” from Brokerages

Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) have been given an average recommendation of “Hold” by the thirteen research firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $19.80.

A number of equities research analysts have issued reports on INO shares. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, October 25th. BidaskClub downgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 27th. ValuEngine downgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. Zacks Investment Research downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 13th. Finally, Maxim Group set a $12.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, January 2nd.

Shares of Inovio Pharmaceuticals (INO) opened at $4.20 on Tuesday. Inovio Pharmaceuticals has a 12-month low of $3.76 and a 12-month high of $9.86. The stock has a market cap of $379.24, a P/E ratio of -3.56 and a beta of 2.54.

Several institutional investors have recently added to or reduced their stakes in INO. Alliancebernstein L.P. raised its holdings in shares of Inovio Pharmaceuticals by 23.9% during the 2nd quarter. Alliancebernstein L.P. now owns 95,500 shares of the biopharmaceutical company’s stock valued at $749,000 after purchasing an additional 18,400 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Inovio Pharmaceuticals by 5.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 21,000 shares of the biopharmaceutical company’s stock worth $164,000 after acquiring an additional 1,000 shares during the period. UBS Asset Management Americas Inc. raised its holdings in Inovio Pharmaceuticals by 0.4% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 25,710 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 92 shares during the period. Northern Trust Corp raised its holdings in Inovio Pharmaceuticals by 2.8% in the 2nd quarter. Northern Trust Corp now owns 896,472 shares of the biopharmaceutical company’s stock worth $7,028,000 after acquiring an additional 24,366 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Inovio Pharmaceuticals by 4.2% in the 2nd quarter. Vanguard Group Inc. now owns 3,227,219 shares of the biopharmaceutical company’s stock worth $25,301,000 after acquiring an additional 129,164 shares during the period. Institutional investors and hedge funds own 33.42% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first posted by Week Herald and is the property of of Week Herald. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://weekherald.com/2018/02/20/inovio-pharmaceuticals-inc-ino-receives-consensus-rating-of-hold-from-brokerages.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply